Brief: Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
03/12/2020 13:11
Dec 3 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX REPORTS POSITIVE INTERIM RESULTS FROM PHASE II
CLINICAL
TRIAL EVALUATING ALLOCETRA IN SEVERE AND CRITICAL COVID-19
PATIENTS
* ENLIVEX THERAPEUTICS LTD - 100% PATIENTS TREATED THROUGH
NOV
26, 2020 HAD COMPLETE RECOVERY FROM RESPECTIVE SEVERE/CRITICAL
CONDITION
* ENLIVEX THERAPEUTICS LTD - ALLOCETRA TREATMENT HAS BEEN
WELL
TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS
Source text for Eikon: ID:nGNX5frhsF
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment